Novav
Novavax (NVAX) got here out with a quarterly lack of $1.13 per share versus the Zacks Consensus Estimate of a lack of $1.08. This compares to lack of $2.60 per share a yr in the past. These figures are adjusted for non-recurring objects.
This quarterly report represents an earnings shock of -4.63%. 1 / 4 in the past, it was anticipated that this vaccine maker would publish a lack of $1.02 per share when it really produced a lack of $1.03, delivering a shock of -0.98%.
Over the past 4 quarters, the corporate has surpassed consensus EPS estimates simply as soon as.
Novavax, which belongs to the Zacks Medical – Biomedical and Genetics business, posted revenues of $8.82 million for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 120.95%. This compares to year-ago revenues of $6.13 million. The corporate has topped consensus income estimates simply as soon as during the last 4 quarters.
The sustainability of the inventory’s rapid…